Publications:

Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Translational Oncology

Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW

Publication Date: 2021-11

Variant appearance in text: ALK: T1151I

PubMed Link: 34365220

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page